MMP-2与TIMP-2在浸润性乳腺癌组织表达的临床意义及相关性研究

目的 :研究乳腺癌组织中基质金属蛋白酶 (MMP 2 )和金属蛋白酶组织抑制因子(TIMP 2 )的表达与临床病理学特征及预后的关系。方法 :应用SP免疫组化方法检测 78例浸润性乳腺癌组织和 10例乳腺良性病变中MMP 2、TIMP 2的半定量表达情况。结果 :1)在78例乳腺癌组织中 ,MMP 2、TIMP 2的阳性表达率分别为 74 3 % ( 5 8/78)和 3 9 7% ( 3 1/78) ,与对照组比较差异有统计学意义 ,P <0 0 1;两者表达呈负相关 ,rs=-0 43 7,P <0 0 1。 2 )MMP 2表达与乳腺癌原发肿瘤大小呈显著正相关 ,rs=0 3 74,P <0 0 1,与组织学分级相关 ,分级越高其阳性表达率就越高 ,rs=0 60 6,P <0 0 1;TIMP 2的表达与肿瘤大小呈负相关rs=-0 2 88,P <0 0 5 ;与组织学分级呈负相关 ,rs=-0 3 77,P <0 0 1。MMP 2阳性表达与腋窝淋巴结转移呈正相关 ,rs=0 45 4,P <0 0 1;TIMP 2的表达与腋窝淋巴结转移呈负相关 ,rs=-0 2 61,P<0 0 5。MMP 2阳性表达与 5年生存率呈负相关 ,P <0 0 1;TIMP 2与 5年生存率呈正相关 ,P<0 0 1。结论 :乳腺癌组织中MMP 2与TIMP 2的表达与肿瘤转移及患者预后密切相关。

Prognostic significance of MMP-2 and TIMP-2 expression in infiltrating breast cancer

OBJECTIVE:To investigate the expression of matrix metalloproteinase-2 and tissue inhibitor metalloproteinase-2 and its clinicopathological characteristics and prognosis.METHODS: Immunohistochemical SP method was performed to detect MMP-2 and TIMP-2 in 78 infiltrative ductal breast cancer. RESULTS:1)The expression rate of MMP-2 in infiltrative breast cancer and significantly higher than that in benign breast diseases, P<0.01. the expression of TIMP-2 were 39.7% and was significantly higher than that in control group, P<0.01.Expression of MMP-2 was negatively correlated with expression of TIMP-2, r s=-0.437, P<0.01. 2)the expression of MMP-2 was positively correlated to tumor size, r s=0.374,P<0.01; positively correlated to histological grade, r s=0.606,P<0.01; positively correlated to lymph node metastasis, r s=0.454,P<0.01; and was negatively correlated to 5-year survival time (P<0.01). The expression of TIMP-2 was negatively correlated to tumor size r s=-0.288,P<0.05;negatively correlated to histological grade,r s=-0.377,P<0.01; negatively correlated to lymph node metastasis r s=-0.261,P<0.05;and was positively correlated to 5-years survival time(P<0.01).CONCLUSIONS: the expressions of MMP-2 and TIMP-2 are closely correlated to tumor size,histological grade, lymph node metastasis and prognosis in breast cancer.